Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
scientific article published on 19 April 2018
Author/s
author: Brian K Link, Corinne Haioun, Umar Farooq, Sergei Syrbu, George J Weiner, Gilles Salles, Susan L Slager, Richard Delarue, Thierry J Molina, James R Cerhan, Carrie A Thompson, Cristine Allmer, Olivier Fitoussi
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.